Aytu BioPharma (NASDAQ:AYTU) Downgraded by Zacks Research to Strong Sell

Aytu BioPharma (NASDAQ:AYTU) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

AYTU has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Friday, January 9th. Ascendiant Capital Markets boosted their price objective on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Finally, Wall Street Zen upgraded shares of Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.33.

Aytu BioPharma Price Performance

AYTU stock opened at $2.64 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. The business has a 50-day simple moving average of $2.51 and a two-hundred day simple moving average of $2.38. The company has a market capitalization of $28.33 million, a P/E ratio of -0.69 and a beta of 0.27. Aytu BioPharma has a 52-week low of $0.95 and a 52-week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The company had revenue of $15.17 million for the quarter, compared to analysts’ expectations of $12.17 million.

Hedge Funds Weigh In On Aytu BioPharma

Large investors have recently modified their holdings of the company. Daytona Street Capital LLC purchased a new stake in Aytu BioPharma in the 4th quarter worth approximately $26,000. Rothschild Wealth LLC bought a new position in Aytu BioPharma in the 4th quarter worth about $52,000. Dimensional Fund Advisors LP purchased a new stake in shares of Aytu BioPharma in the 3rd quarter valued at about $58,000. Bellevue Asset Management LLC bought a new stake in shares of Aytu BioPharma during the 4th quarter valued at about $65,000. Finally, XTX Topco Ltd purchased a new position in shares of Aytu BioPharma during the fourth quarter worth about $67,000. 33.49% of the stock is currently owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.